Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy.
作者信息
Gachoud David, Bertelli Claire, Rufer Nathalie
机构信息
Department of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Medical Education Unit, School of Medicine, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
出版信息
Br J Haematol. 2023 Jan;200(2):e25-e27. doi: 10.1111/bjh.18540. Epub 2022 Nov 10.
Abstract
摘要
相似文献
1
Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy.了解指导使用新冠康复期血浆疗法治疗B细胞耗竭患者的最佳实践参数。
Br J Haematol. 2023 Jan;200(2):e25-e27. doi: 10.1111/bjh.18540. Epub 2022 Nov 10.
2
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.在 B 细胞耗竭患者中使用恢复期血浆成功治疗 COVID-19 感染可能会促进细胞免疫。
Eur J Immunol. 2021 Oct;51(10):2478-2484. doi: 10.1002/eji.202149277. Epub 2021 Sep 3.
3
Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients.25 例 B 细胞耗竭患者接受恢复期血浆治疗新型冠状病毒肺炎的效果。
Clin Infect Dis. 2022 Apr 9;74(7):1271-1274. doi: 10.1093/cid/ciab647.
4
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
5
Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.恢复期血浆在免疫功能低下和脆弱人群中预防和治疗 SARS-CoV-2 的潜在用途。
Expert Rev Vaccines. 2022 Jul;21(7):877-884. doi: 10.1080/14760584.2021.1932475. Epub 2021 May 27.
6
SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.严重急性呼吸综合征冠状病毒2变体与康复期血浆：现实、谬误与机遇
J Clin Invest. 2021 Apr 1;131(7). doi: 10.1172/JCI148832.
7
Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.免疫功能低下患者的恢复期血浆介导的 SARS-CoV-2 病毒清除，无 B 细胞恢复。
Int J Mol Sci. 2021 Aug 18;22(16):8902. doi: 10.3390/ijms22168902.
8
Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.早期使用单克隆抗体或恢复期血浆可降低未接种疫苗的 COVID-19 高危患者的死亡率。
Viruses. 2022 Dec 30;15(1):119. doi: 10.3390/v15010119.
9
Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.用恢复期血浆和基于血浆的产品治疗 B 细胞耗竭的 COVID-19 患者。
Clin Immunol. 2021 Jun;227:108723. doi: 10.1016/j.clim.2021.108723. Epub 2021 Apr 7.
10
Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors.重复恢复期血浆捐献者体内抗SARS-CoV-2抗体的动态变化
Transfus Apher Sci. 2021 Dec;60(6):103216. doi: 10.1016/j.transci.2021.103216. Epub 2021 Jul 22.
引用本文的文献
1
Could the Adoptive Transfer of Memory Lymphocytes be an Alternative Treatment for Infections?记忆淋巴细胞的过继转移可否作为感染的一种替代治疗方法？
Int J Mol Sci. 2024 Sep 30;25(19):10550. doi: 10.3390/ijms251910550.
2
Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-Infected Hamsters.疫苗增强的新冠病毒复制减少并加速感染清除，尽管在感染 SARS-CoV-2 的仓鼠中短暂增强了疾病。
J Infect Dis. 2024 Jun 14;229(6):1702-1710. doi: 10.1093/infdis/jiad568.
3
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.COVID-19 恢复期血浆治疗免疫功能低下患者：系统评价和荟萃分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
本文引用的文献
1
Lower anti-spike levels in B-cell-depleted patients after convalescent plasma transfusion suggest the need for repeated doses.康复期血浆输注后B细胞耗竭患者的抗刺突水平较低，提示需要重复给药。
Br J Haematol. 2023 Jan;200(2):e22-e24. doi: 10.1111/bjh.18544. Epub 2022 Nov 7.
2
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.分析不同接种和未接种康复期血浆来源中针对 SARS-CoV-2 奥密克戎的中和抗体效价。
Nat Commun. 2022 Oct 29;13(1):6478. doi: 10.1038/s41467-022-33864-y.
3
Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents.COVID-19 患者在预先接触或不接触 B 细胞耗竭剂的情况下接受血浆治疗后的抗体反应和病毒在体内进化。
Br J Haematol. 2022 Nov;199(4):549-559. doi: 10.1111/bjh.18450. Epub 2022 Sep 13.
4
Monoclonal antibody therapies against SARS-CoV-2.针对 SARS-CoV-2 的单克隆抗体疗法。
Lancet Infect Dis. 2022 Nov;22(11):e311-e326. doi: 10.1016/S1473-3099(22)00311-5. Epub 2022 Jul 5.
5
Boosting immunity to Omicron.增强对奥密克戎的免疫力。
Nat Med. 2022 Mar;28(3):445-446. doi: 10.1038/s41591-022-01727-0.
6
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.SARS-CoV-2 mRNA 疫苗接种引起的中和抗体反应随时间推移而减弱，并因突破性感染而增强。
Sci Transl Med. 2022 Mar 23;14(637):eabn8057. doi: 10.1126/scitranslmed.abn8057.
7
Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies.用于 COVID19 恢复期血浆治疗的患者血液管理：亲和力和供体-受者之间中和抗体浓度的差异相关性。
Clin Microbiol Infect. 2021 Jul;27(7):987-992. doi: 10.1016/j.cmi.2021.04.003. Epub 2021 Apr 17.
8
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.mRNA疫苗接种可增强由SARS-CoV-2感染引发的交叉变异中和抗体。
Science. 2021 Mar 25;372(6549):1413-8. doi: 10.1126/science.abg9175.
9
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.恢复期血浆抗体水平与新冠死亡风险。
N Engl J Med. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13.
10
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.早期高滴度血浆疗法预防老年人重症 COVID-19。
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
Zotero 插件